Differential Effect of Troglitazone on the Human Bile Acid Transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric Mouse

Foster JR, Jacobsen M, Kenna G, Schulz-Utermoehl T, Morikawa Y, Salmu J, Wilson ID.
Toxicologic Pathology, 2012 Dec;40(8):1106-16.

Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers

Samuelsson K, Pickup K, Sarda S, Swales JG, Morikawa Y, Schulz-Utermoehl T, Hutchison M, Wilson ID.
Xenobiotica. 2012 Nov;42(11):1128-37.

Mice with liver composed of human hepatocytes as an animal model for drug testing.

Yoshizato K, Tateno C, Utoh R.

Curr Drug Discov Technol. 2012 Mar;9(1):63-76. Review.

Chimeric mice with humanized liver: mechanism of hepatic hyperplasia induction.

Tateno C.

生化学　2012 Aug;84(8):699-706.

Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication.

Chayama K, Hayes CN, Imamura M.
Hepatol Res. 2012 Sep;42(9):841-53.

ヒト肝細胞キメラマウスを用いた抗肝炎ウイルス薬効評価系

加国雅和、立野知世

ファルマシア 2012; 48(10): 956-958

Severe necroinflammatory reaction caused by natural killer by Fas/FasL interaction and dendritic cells in human hepatocyte chimeric mouse.

Okazaki A, Hiraga N, Imamura M, Nelson Hayes C, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, Yoshizato K, Ohdan H, Chayama K.
Hepatology. 2012 Aug;56(2):555-66.

An orally available, small-molecule interferon inhibits viral replication

Hideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, Hitoshi Yoshino, Hiroshi Ohmori, Motooki Ashihara, Yuichi Hirata, Atsunori Ohta, Hiroshi Sakamoto, Natsuko Hada, Asao Katsume, Michinori Kohara, Kazumi Morikawa, Takuo Tsukuda, Nobuo Shimma, Graham R. Foster, William Alazawi, Yuko Aoki, Mikio Arisawa & Masayuki Sudoh
Scientific Reports Volume: 2,Article number:259

Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.
Nat Med. 2012 Jan 8;18(2):281-5

Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice

Ype P. de Jong1,2, Charles M. Rice1, Alexander Ploss1,

J Hepatol.2011; 54:848–850

Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton’s tyrosine kinase inhibitor.

Liu L, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC Jr, Liao XC, Lubach JW, Deese A, Sowell CG, Currie KS, Young WB, Khojasteh SC, Hop CE, Wong H.
Drug Metab Dispos. 2011 Oct;39(10):1840-9.

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.

Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K.
Hepatology. 2011 Sep 2;54(3):764-71.

Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.

Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.
Hepatology. 2011 Sep 2;54(3):781-8.

Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes.

Takano T, Tsukiyama-Kohara K, Hayashi M, Hirata Y, Satoh M, Tokunaga Y, Tateno C, Hayashi Y, Hishima T, Funata N, Sudo M, Kohara M.

J Hepatol. 2011 Sep;55(3):512-21

An experimental mouse model for hepatitis C virus.

Kimura K, Kohara M.

Exp Anim. 2011;60(2):93-100. Review.

Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice.

Tsuge M, Takahashi S, Hiraga N, Fujimoto Y, Zhang Y, Mitsui F, Abe H, Kawaoka T, Imamura M, Ochi H, Hayes CN, Chayama K.
J Infect Dis. 2011 Jul 15;204(2):224-8.

ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.

Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.
J Hepatol. 2011 Jul;55(1):11-8. Epub 2010 Nov 29.

Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism.

De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C.
Xenobiotica. 2011 Jun;41(6):464-75.

EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKea
Nat Med. 2011 May;17(5):589-95.

Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.

Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K.
J Hepatol. 2011 May;54(5):872-8